Friday, 3 May 2013

Ultrasound Systems Market to 2019 - Technological Advancements, Wide Applications and Device Portability to Drive Future Growth - Reports Corner


For complete information about the report, please visit our website

https://www.reportscorner.com/reports/15626/Ultrasound-Systems-Market-to-2019---Technological-Advancements,-Wide-Applications-and-Device-Portability-to-Drive-Future-Growth/


Global Ultrasound Systems Market Forecast to Exceed $7 billion by 2019 at Compound Annual Growth Rate of 7%

The global ultrasound systems market was valued at $4.6 billion in 2012 and is forecast to increase at a Compound Annual Growth Rate (CAGR) of 7%. The future growth of the market is expected to be driven by technological advancements, the development of new imaging technologies such as 3D and 4D ultrasound imaging, an increased number of applications for ultrasound systems, and the penetration of portable and color doppler ultrasound systems into the market. The unfavorable reimbursement scenario in developed economies such as the US and Europe is expected to have a negative impact upon demand during the forecast period.

The US Continues to be Largest Market for Ultrasound Systems

The US was the largest market for ultrasound systems in 2012, when it was valued at $1.5 billion. The US market, which accounted for 33% of global revenue in 2011, is highly penetrated and is primarily a replacement market for ultrasound systems. An increasing number of applications, and the adoption of fusion technologies such as Magnetic Resonance Imaging (MRI) guided High Intensity Focused Ultrasound (HIFU), are also expected to be major drivers for future growth.

Leading Five Companies Account for 74% of Global Ultrasound Systems Market

In 2011, GE Healthcare was the leading company in the global ultrasound systems market, with a share of 25%, followed by Philips Healthcare with 19%. The leading five companies accounted for 74% of the global ultrasound systems market. Companies are focusing increasingly on investment in emerging economies and advancing the portability of ultrasound systems. Companies are also focusing on enhancing the quality of images, while limiting any increases in the direct costs involved in the installation of ultrasound systems.

Technological Advancement, Increased Applications and Device Portability to Drive Future Growth

Technological advancement, an increased number of applications and portability of ultrasound systems are expected to drive future growth. Technological advancements such as 3D/4D imaging, contrast imaging, directional flow imaging, and software applications provide benefits such as enhanced image quality, real time diagnosis, and improved examination of patient. An increasing number of applications such as electrograph, Endoscopic Bronchial Ultrasound (EBUS) and Endoscopic Ultrasound (EUS) due to improved portability are other drivers for future growth.

Rapidly Aging Global Population and Increasing Healthcare Expenditure in Developing Economies to Continue to Drive Growth

The rapid aging of the global population and the low penetration of ultrasound systems in developing economies such as India and China continue to be major drivers for the future growth of the market. The aging of the global population is resulting in the increased prevalence of chronic disease conditions. Worldwide, there were almost 810 million people aged 60 years or older in 2012, and this number is expected to exceed 2 billion in 2050 (United Nations, 2012). The increased prevalence of chronic disease conditions will continue to drive ultrasound procedure volumes during the forecast period.


Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players - Reports Corner



For complete information about the report, please visit our website

https://www.reportscorner.com/reports/15625/Japan-Pharmaceutical-Market-Outlook---Deregulation-and-More-Efficient-New-Drug-Approval-Process-Attract-Foreign-Investment-and-Improve-the-Competitiveness-of-Japanese-Players/



The Declining and Rapidly Aging Population Presents Significant Challenges to the Healthcare System and Economy as a Whole

Japan had a population of 127,817,277 in 2011, making it the 10th most populated country in the world (The World Bank, 2012). However, since 2005, as the number of deaths exceeded that of births, the population has declined. Without significant government intervention, the depopulation process is expected to continue.

The proportion of people aged 65 or over is 23.3% and projected to reach 29.1% by 2020 and almost 40% by 2050 (Statistical Research and Training Institute, 2012).

These demographic changes will present further challenges to a stagnating economy, which, as the data in this report confirms, is already struggling with reduced economic growth. A diminishing workforce and falling productivity levels will likely add to the economic difficulties Japan is experiencing.

The associated increase in disease burden has also had implications for the healthcare system. Healthcare expenditure has risen, and is set to rise further as the population continues to age.

In 2010, Japan’s healthcare spending per capita was $4,065.4, a significant increase from 2005.

Japan’s universal healthcare system may therefore prove unsustainable as the government looks to control spending. A combination of pro-generic policies, government initiatives to prevent lifestyle diseases, and higher copayments should help to keep healthcare expenditure under control.

Regulatory Reform will Continue to Attract Foreign Pharmaceutical Companies

The ongoing deregulation of the Japanese pharmaceutical industry has made it an attractive market for big pharma. Improvements to the new drug approval process have significantly shortened the approval time. Consultation services provided by approval bodies have been expanded and improved, approval standards have been clarified and the number of trained personnel involved in the review process has increased.

Many of these changes have occurred following the introduction of a number of plans and government policies. Plans are currently being implemented to shorten the review period and improve cooperation with other countries, particularly Western and other Asian nations, such as the Second Medium Range Plan (2009–2014), which includes the International Strategic Plan.

In April 2007, the government introduced the 5-Year Strategy for the Creation of Innovative Pharmaceuticals and Medical Devices, which contributed towards the reduction in lag time associated with new product approvals.

In addition to attracting foreign investment, deregulation has also improved the competitiveness of Japan’s pharmaceutical companies. The market now consists of multinational players such as Takeda and Daiichi Sankyo, who market leading products globally.
Takeda Maintains its Position as the Leading Company in the Japanese Pharmaceutical Industry

Takeda maintained its position as the leader in Japan’s pharmaceutical industry in 2012, with revenues of $18.9 billion. This was followed by Otsuka Holdings, Astellas, Daiichi Sankyo and Eisai.

M&A activity has become a common theme within the global pharmaceutical industry. This is often a strategic response to patent expirations, reduced R&D productivity and the need to cut costs.

The Japanese pharmaceutical industry has followed this trend. Although historically dependent on domestic R&D, the recent globalization of Japanese companies has been driven by enhanced M&A activity. Significant deals have been completed in the US, Europe and developing nations, such as China, India and Brazil.

With a total of 20 M&A, including two recently announced, Takeda has been the most active Japanese company.

The M&A strategy is seen as necessary for pharmaceutical companies keen to expand product pipelines following patent expirations and gain access to untapped markets. It is hoped that such strategic measures will help develop or maintain growth and revenue.

Future of the Brazilian Defense Industry - Market Attractiveness, Competitive Landscape and Forecasts to 2018 - Reports Corner


For complete information about the report, please visit our website
https://www.reportscorner.com/reports/15627/Future-of-the-Brazilian-Defense-Industry---Market-Attractiveness,-Competitive-Landscape-and-Forecasts-to-2018/

Product Synopsis
This report is the result of SDI's extensive market and company research covering the Brazilian defense industry, and provides detailed analysis of both historic and forecast defense industry values including key growth stimulators, analysis of the leading companies in the industry, and key news.

Introduction and Landscape
Why was the report written?
The Future of the Brazilian Defense Industry - Market Attractiveness, Competitive Landscape and Forecasts to 2018 offers the reader an insight into the market opportunities and entry strategies adopted by foreign original equipment manufacturers (OEMs) to gain a market share in the Brazilian defense industry.

What is the current market landscape and what is changing?
Brazilian defense expenditure increased at a CAGR of 8.29% during the review period and valued US$35.85 billion in 2013. The focus of the Brazilian government will be on the modernization of its armed forces, participation in peacekeeping operations, and military procurements.

What are the key drivers behind recent market changes?
The modernization of the armed forces, development of indigenous defense capabilities, and large defense       procurement projects are the major drivers of the Brazilian defense industry.

What makes this report unique and essential to read?
The Future of the Brazilian Defense Industry - Market Attractiveness, Competitive Landscape and Forecasts to 2018 provides detailed analysis of the current industry size and growth expectations from 2014 to 2018, including highlights of key growth stimulators. It also benchmarks the industry against key global markets and provides a detailed understanding of emerging opportunities in specific areas.

Key Features and Benefits
The report provides detailed analysis of the current industry size and growth expectations from 2014 to 2018, including highlights of key growth stimulators, and also benchmarks the industry against key global markets and provides a detailed understanding of emerging opportunities in specific areas.

The report includes trend analysis of imports and exports, together with their implications and impact on the Brazilian defense industry.

The report covers five forces analysis to identify various power centers in the industry and how these are expected to develop in the future.

The report allows readers to identify possible ways to enter the market, together with detailed descriptions of how existing companies have entered the market, including key contracts, alliances, and strategic initiatives.

The report helps the reader to understand the competitive landscape of the defense industry in Brazil. It provides an overview of key defense companies, both domestic and foreign, together with insights such as key alliances, strategic initiatives, and a brief financial analysis.

Key Market Issues
Brazil has a strict offset obligation for defense deals, equivalent to 100% of the contract value. This has proved a challenge for those foreign OEMs whose government has a policy of limited technology transfer, including the US-based company Boeing. Moreover, Brazil's offset policy requires that defense contracts use domestic companies for the manufacture and assembly of defense systems. A number of foreign OEMs have agreed to such offset requirements due to the availability of inexpensive labor and raw materials in the country. However, a significant portion of these companies are reluctant to share proprietary information with Brazil, and often fail to supply defense systems to the country as a consequence. These rigorous requirements by Brazil often delay the approval of defense deals.]

A significant challenge faced by defense suppliers to Brazil is the time taken by the Ministry of Defense to ratify defense deals. As defense procurements occur through competitive bidding, competing companies must undergo technical compliance checks, after which the ministry enters a lengthy negotiation process with bidders, designed to secure the maximum technology transfer at the lowest price. As such, the ratification process is further delayed by long negotiation periods and competing offers given by the various defense firms. Examples include the delay in selecting a supplier for the fourth-generation fighter jets and the delayed purchase of armored personnel carriers from the Italian branch of Invesco Ltd.Despite having the eleventh-largest defense expenditure globally, Brazil only allocates around 6-7% of its total defense expenditure to arms procurement. The country currently allocates 41% of its defense budget towards providing pensions for retired military personnel, and a significant amount is spent on the administration of its defense forces. Although domestic advancements by Brazilian defense firms are fueling the component procurement market, the deal value for these components is often small. This results in the Brazilian defense industry appearing as a relatively less attractive investment opportunity for foreign OEMs.

Key Highlights
All defense procurement and acquisitions made by the Ministry of Defense and associated bodies follow a competitive bidding process. The Ministry of Defense decides which company from which to procure equipment, depending on whether the equipment complies with the ministry's requirements, which company offers the lowest price, and which company offers the most technology transfer. The rule applies for both domestic and foreign suppliers without any preferential treatment for domestic suppliers.

Brazilian aircraft imports account for almost 46% of its total arms procurements, and involves the import of advanced fighter jets and components for the manufacture of indigenous aircraft systems such as helicopters and cargo aircraft. As the country's currency is strengthening and import duties are waved off, importing aircraft seems to be lucrative for the country. The country's naval procurements include submarines from Brazil and France. France has emerged as Brazil's leading arms supplier, with 17.5% share in country's total defense imports. On a number of occasions France has offered technology transfer to Brazil, which has helped it secure defense contracts with the country. Brazil supplies engines to Brazilian aircraft and submarine manufacturers, and is the second-largest arms supplier to the country. The implementation of the Amazon Protection System (SIVAM) has lead the country to procure radar and satellite components, most of which are supplied by the US defense firm Raytheon. During the review period, Brazil has also procured missile systems from Israel, the US, and Spain, which included anti-ship, anti-submarine, and beyond visual range missiles.

During 2008-2012, aircraft were the major exported product, with total 81% of the defense exports. This largest percentage of aircraft can be attributed to multiple deals of Embraer with foreign countries like Chile, Ecuador and Colombia etc.

Breast Cancer - Pipeline Review, H1 2013 - Reports Corner



For complete information about the report, please visit our website

https://www.reportscorner.com/reports/15403/Breast-Cancer---Pipeline-Review,-H1-2013/



Global Markets Direct's, 'Breast Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. Breast Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Breast Cancer.
- A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Breast Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Breast Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2013 - Reports Corner


For complete information about the report, please visit our website


https://www.reportscorner.com/reports/15415/Kidney-Cancer-(Renal-Cell-Cancer)---Pipeline-Review,-H1-2013/

Global Markets Direct's, 'Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer (Renal Cell Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer (Renal Cell Cancer). Kidney Cancer (Renal Cell Cancer) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Kidney Cancer (Renal Cell Cancer).
- A review of the Kidney Cancer (Renal Cell Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Kidney Cancer (Renal Cell Cancer) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Kidney Cancer (Renal Cell Cancer).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Memory Impairment - Pipeline Review, H1 2013 - Reports Corner


For complete information about the report, please visit our website


https://www.reportscorner.com/reports/15464/Memory-Impairment---Pipeline-Review,-H1-2013/


Global Markets Direct's, 'Memory Impairment - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Memory Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Memory Impairment. Memory Impairment - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Memory Impairment.
- A review of the Memory Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Memory Impairment pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Memory Impairment.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Memory Impairment pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Diabetic Macular Edema Pipeline Review, H1 2013 - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/15422/Diabetic-Macular-Edema---Pipeline-Review,-H1-2013/



Global Markets Direct's, 'Diabetic Macular Edema - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema. Diabetic Macular Edema - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Diabetic Macular Edema.
- A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetic Macular Edema pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema.
- Identify emerging players with potentially strong product portfolio and   design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by   identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.